AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
SFNP 2022 – Alnylam takes heart from its Onpattro follow-on
But further data do not shed much light on Onpattro’s chances in Apollo-B.
Proqr eyes its first big test
With pivotal sepofarsen data due, the group will hope to get one up on Editas.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
